Every 424B that Inventiva S.A. (IVA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow IVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IVA filings page.
We are offering 27,272,727 ADSs, each representing one ordinary share. The offering price is $4.40 per ADS for gross proceeds of $119,999,999 and estimated net proceeds of approximately $110.8M (€95.2M). We currently intend to use the net proceeds to repay in full our EIB loans and, together with proceeds from a new debt financing, to fund the repurchase of a portion of the EIB warrants; remaining funds under that debt commitment would fund continued development and potential commercialization of lanifibranor and general corporate purposes. The offering and related financings are interlinked: the Subscription Agreement with BlackRock and Claret and the EIB Master Agreement are conditioned on this equity financing and certain other conditions, and Tranche A/B initial debt closings are expected in mid-June 2026, subject to those conditions.
Inventiva S.A. (IVA) launched a primary offering of 38,961,038 American Depositary Shares at $3.85 per ADS under its shelf registration. The pricing implies a total offering size of $149,999,996, with underwriting commissions of $8,999,999 and estimated net proceeds of approximately $140.1 million. The company also granted underwriters a 30‑day option to purchase up to 5,844,155 additional ADSs at the public offering price, less commissions.
Inventiva plans to use roughly 80% of the proceeds to fund its NATiV3 Phase 3 MASH trial, prepare and initiate an outcomes trial, and support commercialization activities, and about 20% for working capital and general corporate purposes. Ordinary shares outstanding are expected to be 178,112,312 after the offering, or 183,956,467 if the option is fully exercised. The company notes immediate dilution of $3.12 per ADS to new investors.
Inventiva S.A. launched a preliminary prospectus supplement for a $125,000,000 primary offering of American Depositary Shares (ADSs), each representing one ordinary share. The ADSs trade on Nasdaq under “IVA,” and the ordinary shares trade on Euronext Paris as “IVA.”
The company states it will receive the proceeds and has granted underwriters a 30‑day option to purchase additional ADSs. Intended uses include funding the NATiV3 Phase 3 MASH program, preparation/initiation of an outcomes trial, commercialization activities, and general corporate purposes.
As context, cash and cash equivalents were €97.6 million and short‑term deposits were €24.7 million as of September 30, 2025. Ordinary shares outstanding were 139,151,274 as of June 30, 2025, and 146,272,305 as of November 10, 2025. The company discloses it expects to finance activities until the end of Q3 2026 and notes a material uncertainty that may cast significant doubt on its ability to continue as a going concern.